DUSA Pharmaceuticals, Inc.(R) (NASDAQ NMS:DUSA) announced today that it has filed additional lawsuits against physicians in California, Michigan, and Massachusetts, to prevent their continued infringement of DUSA’s patents on methods of treating various disorders with photodynamic therapy (PDT). DUSA’s patents cover the use of compounds such as aminolevulinic acid (ALA) with PDT to treat actinic keratosis, basal cell carcinoma, acne and other dermatological conditions. The suits allege that ALA obtained from sources other than DUSA Pharmaceuticals is being used by physicians, without license from DUSA, to perform treatments that are covered under patents exclusively licensed by DUSA, resulting in direct infringement of these patent(s).
